Targets for antiviral therapy of hepatitis C

Seminars in Liver Disease

Volumn 34, Issue 1, 2014, Pages 9-21

  Rupp, Daniel ^a   Bartenschlager, Ralf ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

cyclophilin A; miR 122; NS3 protease; NS5A; NS5B

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; BILN 2016; BOCEPREVIR; CHAPERONE; CILUPREVIR; CYCLOPHILIN A; DANOPREVIR; FALDAPREVIR; MICRORNA 122; MK 5172; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; SIMEPREVIR; TELAPREVIR; UNCLASSIFIED DRUG; VANIPREVIR; VIROPORIN P7; VIRUS PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; CONFORMATIONAL TRANSITION; GENOME ANALYSIS; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HOST CELL; HUMAN; PATIENT CARE; PRIORITY JOURNAL; RNA REPLICATION; VIRION; VIRUS ENTRY; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; ANTIVIRAL RESISTANCE; CHEMICAL STRUCTURE; DRUG COMBINATION; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; HEPATITIS C, CHRONIC; MOLECULARLY TARGETED THERAPY; PROTEIN CONFORMATION; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; PROTEIN CONFORMATION; TREATMENT OUTCOME; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84899651167     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1371006     Document Type: Article

References (157)

1. Thomas D. L. Global control of hepatitis C: where challenge meets opportunity. Nat Med: 2013; 19 7 850 858
2. Schaefer E. A., Chung R. T. The impact of human gene polymorphisms on HCV infection and disease outcome. Semin Liver Dis: 2011; 31 4 375 386
3. Ghany M. G., Strader D. B., Thomas D. L., Seeff L. B.; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology: 2009; 49 4 1335 1374
4. McHutchison J. G., Everson G. T., Gordon S. C., et al. PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med: 2009; 360 18 1827 1838
5. Kanwal F., White D. L., Tavakoli-Tabasi S., et al. Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities. Clin Gastroenterol Hepatol: 2014; 12 2 327 333, e1
6. Hoffmann L., Ramos J. A., Souza E. V., et al. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. Virol J: 2013; 10 57
7. Poordad F., McCone J. Jr, Bacon B. R., et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med: 2011; 364 13 1195 1206
8. Bacon B. R., Gordon S. C., Lawitz E., et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med: 2011; 364 13 1207 1217
9. Zeuzem S., Andreone P., Pol S., et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med: 2011; 364 25 2417 2428
10. Jacobson I. M., McHutchison J. G., Dusheiko G., et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med: 2011; 364 25 2405 2416
11. Kieffer T. L., Sarrazin C., Miller J. S., et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology: 2007; 46 3 631 639 (Pubitemid 47436107)
12. Aloia A. L., Locarnini S., Beard M. R. Antiviral resistance and direct-acting antiviral agents for HCV. Antivir Ther: 2012; 17 (6 Pt B): 1147 1162
13. Simmonds P. The origin of hepatitis C virus. Curr Top Microbiol Immunol: 2013; 369 1 15
14. André P., Komurian-Pradel F., Deforges S., et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol: 2002; 76 14 6919 6928 (Pubitemid 41246207)
15. Alvisi G., Madan V., Bartenschlager R. Hepatitis C virus and host cell lipids: an intimate connection. RNA Biol: 2011; 8 2 258 269
16. Zeisel M. B., Felmlee D. J., Baumert T. F. Hepatitis C virus entry. Curr Top Microbiol Immunol: 2013; 369 87 112
17. Lupberger J., Zeisel M. B., Xiao F., et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med: 2011; 17 5 589 595
18. Sainz B. Jr, Barretto N., Martin D. N., et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med: 2012; 18 2 281 285
19. Moradpour D., Penin F. Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol: 2013; 369 113 142
20. Gentzsch J., Brohm C., Steinmann E., et al. Hepatitis C virus p7 is critical for capsid assembly and envelopment. PLoS Pathog: 2013; 9 5 e1003355
21. Egger D., Wölk B., Gosert R., et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol: 2002; 76 12 5974 5984 (Pubitemid 34556292)
22. Gosert R., Egger D., Lohmann V., et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol: 2003; 77 9 5487 5492 (Pubitemid 36460961)
23. Romero-Brey I., Merz A., Chiramel A., et al. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog: 2012; 8 12 e1003056
24. Barba G., Harper F., Harada T., et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A: 1997; 94 4 1200 1205 (Pubitemid 27087828)
25. Miyanari Y., Atsuzawa K., Usuda N., et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol: 2007; 9 9 1089 1097 (Pubitemid 47338147)
26. Chang K. S., Jiang J., Cai Z., Luo G. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol: 2007; 81 24 13783 13793 (Pubitemid 350247871)
27. Bartenschlager R., Penin F., Lohmann V., André P. Assembly of infectious hepatitis C virus particles. Trends Microbiol: 2011; 19 2 95 103
28. Lindenbach B. D. Virion assembly and release. Curr Top Microbiol Immunol: 2013; 369 199 218
29. Jones C. T., Catanese M. T., Law L. M., et al. Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol: 2010; 28 2 167 171
30. Witteveldt J., Evans M. J., Bitzegeio J., et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol: 2009; 90 Pt 1 48 58
31. Brimacombe C. L., Grove J., Meredith L. W., et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol: 2011; 85 1 596 605
32. Meylan E., Curran J., Hofmann K., et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature: 2005; 437 7062 1167 1172 (Pubitemid 41509355)
33. Li K., Foy E., Ferreon J. C., et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A: 2005; 102 8 2992 2997 (Pubitemid 40299904)
34. Bartenschlager R., Lohmann V., Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol: 2013; 11 7 482 496
35. Wölk B., Sansonno D., Kräusslich H. G., et al. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol: 2000; 74 5 2293 2304
36. Zhu H., Briggs J. M. Mechanistic role of NS4A and substrate in the activation of HCV NS3 protease. Proteins: 2011; 79 8 2428 2443
37. Love R. A., Parge H. E., Wickersham J. A., et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell: 1996; 87 2 331 342 (Pubitemid 26359010)
38. Kim J. L., Morgenstern K. A., Lin C., et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell: 1996; 87 2 343 355 (Pubitemid 26359011)
39. De Francesco R., Steinkühler C. Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. Curr Top Microbiol Immunol: 2000; 242 149 169 (Pubitemid 29467525)
40. Delang L., Neyts J., Vliegen I., Abrignani S., Neddermann P., De Francesco R. Hepatitis C virus-specific directly acting antiviral drugs. Curr Top Microbiol Immunol: 2013; 369 289 320
41. Brass V., Berke J. M., Montserret R., Blum H. E., Penin F., Moradpour D. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc Natl Acad Sci U S A: 2008; 105 38 14545 14550
42. Clark V. C., Peter J. A., Nelson D. R. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int: 2013; 33 01 80 84
43. Romano K. P., Ali A., Aydin C., et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog: 2012; 8 7 e1002832
44. Llinàs-Brunet M., Bailey M., Fazal G., et al. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg Med Chem Lett: 1998; 8 13 1713 1718 (Pubitemid 28341617)
45. Steinkühler C., Biasiol G., Brunetti M., et al. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry: 1998; 37 25 8899 8905 (Pubitemid 28299658)
46. Lamarre D., Anderson P. C., Bailey M., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature: 2003; 426 6963 186 189 (Pubitemid 37442587)
47. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology: 2010; 138 2 447 462
48. Susser S., Welsch C., Wang Y., et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology: 2009; 50 6 1709 1718
49. Halfon P., Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol: 2011; 55 1 192 206
50. Cento V., Mirabelli C., Salpini R., et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS ONE: 2012; 7 7 e39652
51. López-Labrador F. X., Moya A., Gonzàlez-Candelas F. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther: 2008; 13 4 481 494 (Pubitemid 352016711)
52. Summa V., Ludmerer S. W., McCauley J. A., et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother: 2012; 56 8 4161 4167
53. Ali A., Aydin C., Gildemeister R., et al. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol: 2013;; epub ahead of print
54. Abian O., Vega S., Sancho J., Velazquez-Campoy A. Allosteric inhibitors of the NS3 protease from the hepatitis C virus. PLoS ONE: 2013; 8 7 e69773
55. Yang W., Zhao Y., Fabrycki J., et al. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors. Antimicrob Agents Chemother: 2008; 52 6 2043 2052 (Pubitemid 351758541)
56. Yang W., Sun Y., Hou X., et al. ACH-806, an NS4A antagonist, inhibits hepatitis C virus replication by altering the composition of viral replication complexes. Antimicrob Agents Chemother: 2013; 57 7 3168 3177
57. Saalau-Bethell S. M., Woodhead A. J., Chessari G., et al. Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat Chem Biol: 2012; 8 11 920 925
58. He Y., Staschke K. A., Tan S. L. HCV NS5A: A multifunctional regulator of cellular pathways and virus replication. In: Tan S. L., ed. Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk, UK Horizon Bioscience: 2006; 267 292
59. Penin F., Brass V., Appel N., et al. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem: 2004; 279 39 40835 40843 (Pubitemid 39287681)
60. Tellinghuisen T. L., Marcotrigiano J., Gorbalenya A. E., Rice C. M. The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem: 2004; 279 47 48576 48587 (Pubitemid 39625732)
61. Tellinghuisen T. L., Marcotrigiano J., Rice C. M. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature: 2005; 435 7040 374 379 (Pubitemid 40745549)
62. Love R. A., Brodsky O., Hickey M. J., Wells P. A., Cronin C. N. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol: 2009; 83 9 4395 4403
63. Verdegem D., Badillo A., Wieruszeski J. M., et al. Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A. J Biol Chem: 2011; 286 23 20441 20454
64. Hanoulle X., Verdegem D., Badillo A., Wieruszeski J. M., Penin F., Lippens G. Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded. Biochem Biophys Res Commun: 2009; 381 4 634 638
65. Appel N., Zayas M., Miller S., et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog: 2008; 4 3 e1000035
66. Tellinghuisen T. L., Foss K. L., Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog: 2008; 4 3 e1000032
67. Masaki T., Suzuki R., Murakami K., et al. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol: 2008; 82 16 7964 7976
68. Moradpour D., Evans M. J., Gosert R., et al. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol: 2004; 78 14 7400 7409 (Pubitemid 38915885)
69. Appel N., Pietschmann T., Bartenschlager R. Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. J Virol: 2005; 79 5 3187 3194 (Pubitemid 40270599)
70. Schaller T., Appel N., Koutsoudakis G., et al. Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. J Virol: 2007; 81 9 4591 4603 (Pubitemid 46668657)
71. Kaneko T., Tanji Y., Satoh S., et al. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem Biophys Res Commun: 1994; 205 1 320 326 (Pubitemid 24381628)
72. Quintavalle M., Sambucini S., Summa V., et al. Hepatitis C virus NS5A is a direct substrate of casein kinase I-alpha, a cellular kinase identified by inhibitor affinity chromatography using specific NS5A hyperphosphorylation inhibitors. J Biol Chem: 2007; 282 8 5536 5544 (Pubitemid 47093729)
73. Pietschmann T., Zayas M., Meuleman P., et al. Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog: 2009; 5 6 e1000475
74. Gao M., Nettles R. E., Belema M., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature: 2010; 465 7294 96 100
75. Targett-Adams P., Graham E. J., Middleton J., et al. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. J Virol: 2011; 85 13 6353 6368
76. Lee C., Ma H., Hang J. Q., et al. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology: 2011; 414 1 10 18
77. Fridell R. A., Valera L., Qiu D., Kirk M. J., Wang C., Gao M. Intragenic complementation of hepatitis C virus NS5A RNA replication-defective alleles. J Virol: 2013; 87 4 2320 2329
78. Reiss S., Rebhan I., Backes P., et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe: 2011; 9 1 32 45
79. Paul D., Hoppe S., Saher G., Krijnse-Locker J., Bartenschlager R. Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment. J Virol: 2013; 87 19 10612 10627
80. Belda O., Targett-Adams P. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. Virus Res: 2012; 170 1-2 1 14
81. Guedj J., Dahari H., Rong L., et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A: 2013; 110 10 3991 3996
82. Bressanelli S., Tomei L., Rey F. A., De Francesco R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J Virol: 2002; 76 7 3482 3492 (Pubitemid 34224549)
83. Ago H., Adachi T., Yoshida A., et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure: 1999; 7 11 1417 1426 (Pubitemid 29529882)
84. Lesburg C. A., Cable M. B., Ferrari E., Hong Z., Mannarino A. F., Weber P. C. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol: 1999; 6 10 937 943 (Pubitemid 29463307)
85. Mosley R. T., Edwards T. E., Murakami E., et al. Structure of hepatitis C virus polymerase in complex with primer-template RNA. J Virol: 2012; 86 12 6503 6511
86. Madela K., McGuigan C. Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs. Future Med Chem: 2012; 4 5 625 650
87. Sarrazin C., Hézode C., Zeuzem S., Pawlotsky J. M. Antiviral strategies in hepatitis C virus infection. J Hepatol: 2012; 56 01 S88 S100
88. Powdrill M. H., Bernatchez J. A., Götte M. Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase NS5B. Viruses: 2010; 2 10 2169 2195
89. Shim J., Larson G., Lai V., Naim S., Wu J. Z. Canonical 3′-deoxyribonucleotides as a chain terminator for HCV NS5B RNA-dependent RNA polymerase. Antiviral Res: 2003; 58 3 243 251 (Pubitemid 36589015)
90. Pockros P. J. Nucleoside/nucleotide analogue polymerase inhibitors in development. Clin Liver Dis: 2013; 17 1 105 110
91. Le Pogam S., Jiang W. R., Leveque V., et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology: 2006; 351 2 349 359 (Pubitemid 44108072)
92. Pawlotsky J. M. The science of direct-acting antiviral and host-targeted agent therapy. Antivir Ther: 2012; 17 (6 Pt B): 1109 1117
93. De Francesco R., Carfí A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev: 2007; 59 12 1242 1262 (Pubitemid 350047514)
94. Davis B. C., Thorpe I. F. Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase. Proteins: 2013; 81 1 40 52
95. Di Marco S., Volpari C., Tomei L., et al. Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem: 2005; 280 33 29765 29770 (Pubitemid 41177053)
96. Jopling C. L., Yi M., Lancaster A. M., Lemon S. M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science: 2005; 309 5740 1577 1581 (Pubitemid 41266486)
97. Jopling C. L., Schütz S., Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe: 2008; 4 1 77 85 (Pubitemid 351944051)
98. Jopling C. L. Regulation of hepatitis C virus by microRNA-122. Biochem Soc Trans: 2008; 36 Pt 6 1220 1223
99. Li Y., Masaki T., Lemon S. M. miR-122 and the hepatitis C RNA genome: more than just stability. RNA Biol: 2013; 10 6 919 923
100. Shimakami T., Yamane D., Jangra R. K., et al. Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci U S A: 2012; 109 3 941 946
101. Henke J. I., Goergen D., Zheng J., et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J: 2008; 27 24 3300 3310
102. Randall G., Panis M., Cooper J. D., et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A: 2007; 104 31 12884 12889 (Pubitemid 47255249)
103. Lanford R. E., Hildebrandt-Eriksen E. S., Petri A., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science: 2010; 327 5962 198 201
104. Janssen H. L., Reesink H. W., Lawitz E. J., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med: 2013; 368 18 1685 1694
105. Tsai W. C., Hsu S. D., Hsu C. S., et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest: 2012; 122 8 2884 2897
106. Hsu S. H., Wang B., Kota J., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest: 2012; 122 8 2871 2883
107. Galat A., Bua J. Molecular aspects of cyclophilins mediating therapeutic actions of their ligands. Cell Mol Life Sci: 2010; 67 20 3467 3488
108. Watashi K., Hijikata M., Hosaka M., Yamaji M., Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology: 2003; 38 5 1282 1288 (Pubitemid 37314838)
109. Watashi K., Ishii N., Hijikata M., et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell: 2005; 19 1 111 122 (Pubitemid 40884662)
110. Yang F., Robotham J. M., Nelson H. B., Irsigler A., Kenworthy R., Tang H. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol: 2008; 82 11 5269 5278 (Pubitemid 351705235)
111. Kaul A., Stauffer S., Berger C., et al. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog: 2009; 5 8 e1000546
112. Chatterji U., Bobardt M., Selvarajah S., et al. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem: 2009; 284 25 16998 17005
113. Liu Z., Yang F., Robotham J. M., Tang H. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J Virol: 2009; 83 13 6554 6565
114. Foster T. L., Gallay P., Stonehouse N. J., Harris M. Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner. J Virol: 2011; 85 14 7460 7464
115. Hopkins S., Bobardt M., Chatterji U., Garcia-Rivera J. A., Lim P., Gallay P. A. The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes. Antimicrob Agents Chemother: 2012; 56 7 3888 3897
116. Ciesek S., Steinmann E., Wedemeyer H., et al. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology: 2009; 50 5 1638 1645
117. Madan V., Paul D., Lohmann V., Bartenschlager R. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation. Gastroenterology: 2014; Jan 30. [Epub ahead of print]
118. Inoue K., Sekiyama K., Yamada M., Watanabe T., Yasuda H., Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol: 2003; 38 6 567 572 (Pubitemid 36857388)
119. Flisiak R., Jaroszewicz J., Flisiak I., Łapiński T. Update on alisporivir in treatment of viral hepatitis C. Expert Opin Investig Drugs: 2012; 21 3 375 382
120. Pfefferle S., Schöpf J., Kögl M., et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog: 2011; 7 10 e1002331
121. Goto K., Watashi K., Inoue D., Hijikata M., Shimotohno K. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Sci: 2009; 100 10 1943 1950
122. Chatterji U., Lim P., Bobardt M. D., et al. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J Hepatol: 2010; 53 1 50 56
123. Puyang X., Poulin D. L., Mathy J. E., et al. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrob Agents Chemother: 2010; 54 5 1981 1987
124. Yang F., Robotham J. M., Grise H., et al. A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. PLoS Pathog: 2010; 6 9 e1001118
125. Coelmont L., Hanoulle X., Chatterji U., et al. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS ONE: 2010; 5 10 e13687
126. Zeisel M. B., Fofana I., Fafi-Kremer S., Baumert T. F. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol: 2011; 54 3 566 576
127. Angus A. G., Patel A. H. Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2. Future Microbiol: 2011; 6 3 279 294
128. Meuleman P., Bukh J., Verhoye L., et al. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology: 2011; 53 3 755 762
129. Giang E., Dorner M., Prentoe J. C., et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A: 2012; 109 16 6205 6210
130. Keck Z. Y., Xia J., Wang Y., et al. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog: 2012; 8 4 e1002653
131. OuYang B., Xie S., Berardi M. J., et al. Unusual architecture of the p7 channel from hepatitis C virus. Nature: 2013; 498 7455 521 525
132. Chandler D. E., Penin F., Schulten K., Chipot C. The p7 protein of hepatitis C virus forms structurally plastic, minimalist ion channels. PLOS Comput Biol: 2012; 8 9 e1002702
133. Luik P., Chew C., Aittoniemi J., et al. The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy. Proc Natl Acad Sci U S A: 2009; 106 31 12712 12716
134. Steinmann E., Pietschmann T. Hepatitis C virus p7-a viroporin crucial for virus assembly and an emerging target for antiviral therapy. Viruses: 2010; 2 9 2078 2095
135. Wozniak A. L., Griffin S., Rowlands D., et al. Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production. PLoS Pathog: 2010; 6 9 e1001087
136. Steinmann E., Penin F., Kallis S., Patel A. H., Bartenschlager R., Pietschmann T. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog: 2007; 3 7 e103
137. Carlsson T., Lindahl K., Schvarcz R., et al. HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin. J Viral Hepat: 2000; 7 6 409 413
138. Piai G., Rocco P., Tartaglione M. T., et al. Triple (interferon, ribavirin, amantadine) versus double (interferon, ribavirin) re-therapy for interferon relapser genotype 1b HCV chronic active hepatitis patients. Hepatol Res: 2003; 25 4 355 363 (Pubitemid 36519281)
139. Tabone M., Ercole E., Zaffino C., Sallio Bruno F., Pera A., Bonino F. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. Ital J Gastroenterol Hepatol: 1998; 30 6 611 613 (Pubitemid 29073998)
140. Lundin M., Lindström H., Grönwall C., Persson M. A. Dual topology of the processed hepatitis C virus protein NS4B is influenced by the NS5A protein. J Gen Virol: 2006; 87 Pt 11 3263 3272 (Pubitemid 44608361)
141. Gouttenoire J., Roingeard P., Penin F., Moradpour D. Amphipathic alpha-helix AH2 is a major determinant for the oligomerization of hepatitis C virus nonstructural protein 4B. J Virol: 2010; 84 24 12529 12537
142. Paul D., Romero-Brey I., Gouttenoire J., et al. NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes. J Virol: 2011; 85 14 6963 6976
143. Einav S., Gerber D., Bryson P. D., et al. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol: 2008; 26 9 1019 1027
144. Jones D. M., Patel A. H., Targett-Adams P., McLauchlan J. The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. J Virol: 2009; 83 5 2163 2177
145. Zhang X., Zhang N., Chen G., et al. Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B. Bioorg Med Chem Lett: 2013; 23 13 3947 3953
146. Cho N. J., Dvory-Sobol H., Lee C., et al. Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B. Sci Transl Med: 2010; 2 15 ra6
147. Bryson P. D., Cho N. J., Einav S., et al. A small molecule inhibits HCV replication and alters NS4B's subcellular distribution. Antiviral Res: 2010; 87 1 1 8
148. Ferenci P., Scherzer T. M., Kerschner H., et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology: 2008; 135 5 1561 1567
149. Beinhardt S., Rasoul-Rockenschaub S., Scherzer T. M., Ferenci P. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J Hepatol: 2011; 54 3 591 592, author reply 592-593
150. Bárcena R., Moreno A., Rodríguez-Gandía M. A., et al. Hospital Ramón y Cajal Liver Transplant Group. Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period. J Hepatol: 2013; 58 3 421 426
151. Wagoner J., Negash A., Kane O. J., et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology: 2010; 51 6 1912 1921
152. Blaising J., Lévy P. L., Gondeau C., et al. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell Microbiol: 2013; 15 11 1866 1882
153. Mehrab-Mohseni M., Sendi H., Steuerwald N., Ghosh S., Schrum L. W., Bonkovsky H. L. Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV. World J Gastroenterol: 2011; 17 13 1694 1700
154. Polyak S. J., Oberlies N. H., Pécheur E. I., Dahari H., Ferenci P., Pawlotsky J. M. Silymarin for HCV infection. Antivir Ther: 2013; 18 2 141 147
155. Ahmed-Belkacem A., Ahnou N., Barbotte L., et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology: 2010; 138 3 1112 1122
156. Esser-Nobis K., Romero-Brey I., Ganten T. M., et al. Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology: 2013; 57 3 953 963
157. Guedj J., Dahari H., Pohl R. T., Ferenci P., Perelson A. S. Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol: 2012; 56 5 1019 1024